© 2019 Future Science Group

Unitec House, 2 Albert Place,

London, N3 1QB, UK

Email: info@future-science-group.com
Tel: +44 (0)20 8371 6090

  • LinkedIn - White Circle
  • Facebook - White Circle
  • Twitter - White Circle
  • YouTube - White Circle

News

30 August 2019
Special Focus Issue of Future Oncology highlights how treatment sequencing can optimize cancer therapies.

The Future Science Group (FSG) published journal, Future Oncology, has announced the release of a Special Focus Issue entitled ‘Optimizing treatment sequences in cancer therapies: where are we now?’, highlighting the importance of treatment sequencing for maximizing the success of cancer therapy, and personalizing treatments.

A highlight from the issue includes an updated analysis of the observational GioTag study that assessed outcomes in patients with EGFR mutation-positive non-small-cell lung cancer receiving sequential afatinib and osimertinib in a real-world clinical setting. Another highlight is an interview with Angela Märten exploring the question of treatment sequencing in various fields of oncology, and an Editorial considering the role of liquid biopsies as a non-invasive method of mutation testing compared to tissue biopsies.

We are delighted to have Orazio Caffo as Guest Editor for the Special Focus Issue. Caffo commented: “The introduction of novel agents has made it possible to achieve unprecedented gains in cancer patient survival expectancy but, at the same time, has raised a number of unsolved questions concerning optimal sequencing strategies.”

Rachel Jenkins, Managing Commissioning Editor for Future Oncology, further added: “We are delighted to publish this Special Focus Issue which aims to emphasize the importance and challenges facing this exciting field in cancer therapy. It has been a pleasure to work with Orazio Caffo, and all the contributing authors, to produce such a timely and insightful issue that we hope will ultimately lead to improved patient care in the future."
 
The Guest Editors’ free-access Foreword article is available online here: https://www.futuremedicine.com/doi/10.2217/fon-2019-0415

The full issue is available online here: https://www.futuremedicine.com/toc/fon/15/25
 
About Future Oncology
 
Future Oncology is a MEDLINE-indexed journal, with an impact factor of 2.279. The journal covers the latest scientific and clinical issues, together with the economic and policy issues of relevance to oncologists. The journal delivers essential information in concise, at-a-glance article formats – vital in delivering information to an increasingly time-constrained community. http://www.futuremedicine.com/loi/fon
 
About Future Science Group
 
Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research.  FSG’s portfolio includes two imprints, Future Science and Future Medicine.  In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.
 
The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs.  This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.